The Latest Breaking News from Nasdaq

Amarin Corporation plc (NASDAQ:AMRN) announced a comprehensive cost and organizational restructuring plan to reduce operating costs by approximately $100 million over the next 12 months. The restructuring will enable Amarin to maintain a positive contribution margin in the U.S. while investing in its European market launches and global expansion for Vascepa/Vazkepa. The majority…

AeroClean Technologies Inc's (NASDAQ:AERC) Pūrgo technology has secured U.S. FDA 510(k) clearance, classifying it as a Class II Medical Device. The clearance was granted following examination of the patented Pūrgo device, which utilizes patented germicidal UV-C LED air purification technology that has been proven to eliminate 99.99% of harmful airborne microorganisms, including…

Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 5.77% on an annualized basis producing an average annual return of 17.01%. Currently, Seagen has a market capitalization of $26.17 billion.

Upgrades

Benzinga Pro data, Arcturus Therapeutics (NASDAQ:ARCT) reported Q1 sales of $5.24 million. Earnings fell to a loss of $51.17 million, resulting in a 32.35% decrease from last quarter.

Twitter Inc (NYSE: TWTR) shares are trading lower Monday after Tesla Inc (NASDAQ: TSLA) CEO Elon Musk indicated that the social media company breached obligations under the merger agreement

Benzinga Pro data, Enanta Pharmaceuticals (NASDAQ:ENTA) reported Q2 sales of $18.72 million. Earnings fell to a loss of $33.59 million, resulting in a 11.55% decrease from last quarter.

Infrastructure and Energy (NASDAQ:IEA) brought in sales totaling $360.10 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 185.52%, resulting in a loss of $27.07 million.

SRAX, Inc (NASDAQ:SRAX) reported fourth-quarter FY21 Sequire revenue growth of 170% year-on-year to $9.6 million, missing the consensus of $10.2 million. The continued adoption of its SaaS platform Sequire drove the increase. SRAX held $1.35 million in cash and equivalents. Outlook: SRAX sees Q1 FY22 revenue of $11.5 million in line with the consensus…

According to data from Benzinga Pro, during Q1, Y-mAbs Therapeutics's (NASDAQ:YMAB) reported sales totaled $10.49 million. Despite a 23.92% increase in earnings, the company posted a loss of $28.07 million.

Pulled from Benzinga Pro data, Verra Mobility (NASDAQ:VRRM) showed a loss in earnings since Q4, totaling $10.04 million. Sales, on the other hand, increased by 0.24% to $170.38 million during Q1.